BioPharma Credit grows capital raising to $305m

BioPharma Credit, the UK closed-end investment fund that provides debt funding to the life sciences industry, has priced its latest capital raise, growing the deal to $305m.

  • By Sam Kerr
  • 01 Nov 2018

JP Morgan is global co-coordinator; Goldman Sachs and Canaccord Genuity are bookrunners.

It is the second time that the company has grown the offer over the course of bookbuilding. Last week it increased the deal to $200m form the original $150m target.

The final deal size was for ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 161,597.45 701 8.06%
2 Citi 158,100.45 638 7.89%
3 Bank of America Merrill Lynch 131,322.73 520 6.55%
4 Barclays 126,396.71 489 6.30%
5 HSBC 104,257.54 522 5.20%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Bank of America Merrill Lynch 12,900.23 34 6.65%
2 BNP Paribas 12,334.48 61 6.36%
3 UniCredit 11,196.47 58 5.77%
4 Citi 9,580.75 37 4.94%
5 Deutsche Bank 8,953.95 35 4.62%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Morgan Stanley 5,454.13 25 10.64%
2 JPMorgan 4,766.13 27 9.30%
3 Goldman Sachs 4,280.20 20 8.35%
4 Citi 3,649.88 23 7.12%
5 UBS 3,602.23 16 7.03%